Update on cardiovascular effects of older and newer anti-diabetic medications

Current Medicinal Chemistry

Volumn 25, Issue 13, 2017, Pages 1549-1566

  Eleftheriadou, Ioanna ^a   Grigoropoulou, Pinelopi ^a   Liberopoulos, Evangelos ^b   Liatis, Stavros ^a   Kokkinos, Alexandros ^a   Tentolouris, Nikolaos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cardiovascular events; Dipeptidyl peptidase 4 inhibitors; Glucagon like peptide 1 receptor agonists; Insulin; Metformin; Pioglitazone; Sodium glucose co transporters 2 inhibitors; Sulfonylureas

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; BENZHYDRYL DERIVATIVE; EMPAGLIFLOZIN; GLUCAGON LIKE PEPTIDE; GLUCOSIDE; LIRAGLUTIDE; PIOGLITAZONE; SEMAGLUTIDE; SODIUM GLUCOSE COTRANSPORTER 2;

ALL CAUSE MORTALITY; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR EFFECT; CARDIOVASCULAR MORTALITY; DRUG SAFETY; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; REVIEW; SYSTEMATIC REVIEW; CARDIOVASCULAR DISEASE; COMPLICATION; GLUCOSE BLOOD LEVEL; METABOLISM;

BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDES; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85039999004     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867324666170530075533     Document Type: Review

References (90)

1. Shah A.D.; Langenberg C.; Rapsomaniki E.; Denaxas S.; Pujades-Rodriguez M.; Gale C.P.; Deanfield J.; Smeeth L.; Timmis A.; Hemingway H. Type 2 diabetes and incidence of cardiovascular diseases: A cohort study in 1.9 million people. Lancet Diabetes Endocrinol., 2015, 3, 105-113.
2. Ryden L.; Grant P.J.; Anker S.D.; Berne C.; Cosentino F.; Danchin N.; Deaton C.; Escaned J.; Hammes H.P.; Huikuri H.; Marre M.; Marx N.; Mellbin L.; Ostergren J.; Patrono C.; Seferovic P.; Uva M.S.; Taskinen M.R.; Tendera M.; Tuomilehto J.; Valensi P.; Zamorano J.L.; Achenbach S.; Baumgartner H.; Bax J.J.; Bueno H.; Dean V.; Erol C.; Fagard R.; Ferrari R.; Hasdai D.; Hoes A.W.; Kirchhof P.; Knuuti J.; Kolh P.; Lancellotti P.; Linhart A.; Nihoyannopoulos P.; Piepoli M.F.; Ponikowski P.; Sirnes P.A.; Tamargo J.L.; Torbicki A.; Wijns W.; Windecker S.; De Backer G.; Ezquerra E.A.; Avogaro A.; Badimon L.; Baranova E.; Betteridge J.; Ceriello A.; Funck-Brentano C.; Gulba D.C.; Kjekshus J.K.; Lev E.; Mueller C.; Neyses L.; Nilsson P.M.; Perk J.; Reiner Z.; Sattar N.; Schachinger V.; Scheen A.; Schirmer H.; Stromberg A.; Sudzhaeva S.; Viigimaa M.; Vlachopoulos C.; Xuereb R.G. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur. Heart J., 2013, 34, 3035-3087.
3. Sarwar N.; Gao P.; Seshasai S.R.; Gobin R.; Kaptoge S.; Di Angelantonio E.; Ingelsson E.; Lawlor D.A.; Selvin E.; Stampfer M.; Stehouwer C.D.; Lewington S.; Pennells L.; Thompson A.; Sattar N.; White I.R.; Ray K.K.; Danesh J. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet, 2010, 375, 2215-2222.
4. Centers for Disease Control and Prevention. Diabetes Public Health Resource. Number (in Millions) of Civilian, Non- Institutionalized Persons with Diagnosed Diabetes, United States, 1980-2014. http://www.cdc.gov/diabetes/statistics/prev/national/figpersons.htm(Accessed July 21, 2016).
5. Beckman J.A.; Creager M.A.; Libby P. Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. JAMA, 2002, 287, 2570-2581.
6. Gu K.; Cowie C.C.; Harris M.I. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care, 1998, 21, 1138-1145.
7. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998, 352, 837-853.
8. Holman R.R.; Paul S.K.; Bethel M.A.; Matthews D.R.; Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med., 2008, 359, 1577-1589.
9. Gerstein H.C.; Miller M.E.; Byington R.P.; Goff D.C., Jr.; Bigger J.T.; Buse J.B.; Cushman W.C.; Genuth S.; Ismail- Beigi F.; Grimm R.H., Jr.; Probstfield J.L.; Simons-Morton D.G.; Friedewald W.T. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med., 2008, 358, 2545-2559.
10. Chow E.; Bernjak A.; Williams S.; Fawdry R.A.; Hibbert S.; Freeman J.; Sheridan P.J.; Heller S.R. Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. Diabetes, 2014, 63, 1738-1747.
11. Nordin C. The case for hypoglycaemia as a proarrhythmic event: Basic and clinical evidence. Diabetologia, 2010, 53, 1552-1561.
12. Nissen S.E.; Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med., 2007, 356, 2457-2471.
13. U.S. Department of Health and Human Services. Final Guidance for Industry: Guidance for Industry: Diabetes Mellitus – Evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. U.S. Department of Health and Human Resources; December 2008. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf(Accessed July 21, 2016).
14. European Medicines Agency. Guideline on the Investigation of Drug Interactions; June 21, 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf(Accessed July 21, 2016).
15. American Diabetes Association. Approaches to Glycemic Treatment. Diabetes Care, 2016, 39 Suppl 1, S52-59.
16. Viollet B.; Guigas B.; Sanz Garcia N.; Leclerc J.; Foretz M.; Andreelli F. Cellular and molecular mechanisms of metformin: An overview. Clin. Sci. (Lond)., 2012, 122, 253-270.
17. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998, 352, 854-865.
18. Lamanna C.; Monami M.; Marchionni N.; Mannucci E. Effect of metformin on cardiovascular events and mortality: A meta-analysis of randomized clinical trials. Diabetes Obes. Metab., 2011, 13, 221-228.
19. Maruthur N.M.; Tseng E.; Hutfless S.; Wilson L.M.; Suarez- Cuervo C.; Berger Z.; Chu Y.; Iyoha E.; Segal J.B.; Bolen S. Diabetes Medications as Monotherapy or Metformin- Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Ann. Intern. Med., 2016, 164, 740-751.
20. Holden S.E.; Jenkins-Jones S.; Currie C.J. Association between Insulin Monotherapy versus Insulin plus Metformin and the Risk of All-Cause Mortality and Other Serious Outcomes: A Retrospective Cohort Study. PLoS One, 2016, 11, e0153594.
21. Masoudi F.A.; Inzucchi S.E.; Wang Y.; Havranek E.P.; Foody J.M.; Krumholz H.M. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: An observational study. Circulation, 2005, 111, 583-590.
22. Salpeter S.R.; Greyber E.; Pasternak G.A.; Salpeter E.E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst. Rev., 2010, CD002967.
23. Aguilar D.; Chan W.; Bozkurt B.; Ramasubbu K.; Deswal A. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ. Heart Fail., 2011, 4, 53-58.
24. Schwartz T.B.; Meinert C.L. The UGDP controversy: Thirty-four years of contentious ambiguity laid to rest. Perspect. Biol. Med., 2004, 47, 564-574.
25. A study of the effects of hypoglycemia agents on vascular complications in patients with adult-onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide. Diabetes, 1976, 25, 1129-1153.
26. Schramm T.K.; Gislason G.H.; Vaag A.; Rasmussen J.N.; Folke F.; Hansen M.L.; Fosbol E.L.; Kober L.; Norgaard M.L.; Madsen M.; Hansen P.R.; Torp-Pedersen C. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: A nationwide study. Eur. Heart J., 2011, 32, 1900-1908.
27. Hemmingsen B.; Schroll J.B.; Lund S.S.; Wetterslev J.; Gluud C.; Vaag A.; Sonne D.P.; Lundstrom L.H.; Almdal T. Sulphonylurea monotherapy for patients with type 2 dia-betes mellitus. Cochrane Database Syst. Rev., 2013, 4, CD009008.
28. CAROLINA: Cardiovascular Outcome Study of Linagliptin versus Glimepiride in Patients with Type 2 Diabetes. ClinicalTrials. gov. https://clinicaltrials.gov/ct2/show/NCT01243424(Accessed January 8, 2017).
29. Guardado-Mendoza R.; Prioletta A.; Jimenez-Ceja L.M.; Sosale A.; Folli F. The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus. Arch. Med. Sci., 2013, 9, 936-943.
30. Group N.S.; Holman R.R.; Haffner S.M.; McMurray J.J.; Bethel M.A.; Holzhauer B.; Hua T.A.; Belenkov Y.; Boolell M.; Buse J.B.; Buckley B.M.; Chacra A.R.; Chiang F.T.; Charbonnel B.; Chow C.C.; Davies M.J.; Deedwania P.; Diem P.; Einhorn D.; Fonseca V.; Fulcher G.R.; Gaciong Z.; Gaztambide S.; Giles T.; Horton E.; Ilkova H.; Jenssen T.; Kahn S.E.; Krum H.; Laakso M.; Leiter L.A.; Levitt N.S.; Mareev V.; Martinez F.; Masson C.; Mazzone T.; Meaney E.; Nesto R.; Pan C.; Prager R.; Raptis S.A.; Rutten G.E.; Sandstroem H.; Schaper F.; Scheen A.; Schmitz O.; Sinay I.; Soska V.; Stender S.; Tamas G.; Tognoni G.; Tuomilehto J.; Villamil A.S.; Vozar J.; Califf R.M. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N. Engl. J. Med., 2010, 362, 1463-1476.
31. Chang Y.C.; Chuang L.M.; Lin J.W.; Chen S.T.; Lai M.S.; Chang C.H. Cardiovascular risks associated with secondline oral antidiabetic agents added to metformin in patients with Type 2 diabetes: A nationwide cohort study. Diabet. Med., 2015, 32, 1460-1469.
32. Hauner H. The mode of action of thiazolidinediones. Diabetes Metab. Res. Rev., 2002, 18 Suppl 2, S10-15.
33. Nesto R.W.; Bell D.; Bonow R.O.; Fonseca V.; Grundy S.M.; Horton E.S.; Le Winter M.; Porte D.; Semenkovich C.F.; Smith S.; Young L.H.; Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation, 2003, 108, 2941-2948.
34. Dormandy J.A.; Charbonnel B.; Eckland D.J.; Erdmann E.; Massi-Benedetti M.; Moules I.K.; Skene A.M.; Tan M.H.; Lefebvre P.J.; Murray G.D.; Standl E.; Wilcox R.G.; Wilhelmsen L.; Betteridge J.; Birkeland K.; Golay A.; Heine R.J.; Koranyi L.; Laakso M.; Mokan M.; Norkus A.; Pirags V.; Podar T.; Scheen A.; Scherbaum W.; Schernthaner G.; Schmitz O.; Skrha J.; Smith U.; Taton J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet, 2005, 366, 1279-1289.
35. Lincoff A.M.; Wolski K.; Nicholls S.J.; Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. JAMA, 2007, 298, 1180-1188.
36. Kernan W.N.; Viscoli C.M.; Furie K.L.; Young L.H.; Inzucchi S.E.; Gorman M.; Guarino P.D.; Lovejoy A.M.; Peduzzi P.N.; Conwit R.; Brass L.M.; Schwartz G.G.; Adams H.P., Jr.; Berger L.; Carolei A.; Clark W.; Coull B.; Ford G.A.; Kleindorfer D.; O'Leary J.R.; Parsons M.W.; Ringleb P.; Sen S.; Spence J.D.; Tanne D.; Wang D.; Winder T.R.; Investigators I.T. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N. Engl. J. Med., 2016, 374, 1321-1331.
37. Home P.D.; Pocock S.J.; Beck-Nielsen H.; Curtis P.S.; Gomis R.; Hanefeld M.; Jones N.P.; Komajda M.; McMurray J.J. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial. Lancet, 2009, 373, 2125-2135.
38. Nissen S.E.; Wolski K. Rosiglitazone revisited: An updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch. Intern. Med., 2010, 170, 1191-1201.
39. Rosak C.; Mertes G. Critical evaluation of the role of acarbose in the treatment of diabetes: Patient considerations. Diabetes Metab. Syndr. Obes., 2012, 5, 357-367.
40. Chiasson J.L.; Josse R.G.; Gomis R.; Hanefeld M.; Karasik A.; Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial. JAMA, 2003, 290, 486-494.
41. Hanefeld M.; Cagatay M.; Petrowitsch T.; Neuser D.; Petzinna D.; Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: Meta-analysis of seven long-term studies. Eur. Heart J., 2004, 25, 10-16.
42. Muis M.J.; Bots M.L.; Grobbee D.E.; Stolk R.P. Insulin treatment and cardiovascular disease; friend or foe? A point of view. Diabet. Med., 2005, 22, 118-126.
43. Knatterud G.L.; Klimt C.R.; Levin M.E.; Jacobson M.E.; Goldner M.G. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VII. Mortality and selected nonfatal events with insulin treatment. JAMA, 1978, 240, 37-42.
44. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ, 1997, 314, 1512-1515.
45. Investigators O.T.; Gerstein H.C.; Bosch J.; Dagenais G.R.; Diaz R.; Jung H.; Maggioni A.P.; Pogue J.; Probstfield J.; Ramachandran A.; Riddle M.C.; Ryden L.E.; Yusuf S. Basal insulin and cardiovascular and other outcomes in dysglycemia. N. Engl. J. Med., 2012, 367, 319-328.
46. Currie C.J.; Poole C.D.; Evans M.; Peters J.R.; Morgan C.L. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J. Clin. Endocrinol. Metab., 2013, 98, 668-677.
47. Roumie C.L.; Greevy R.A.; Grijalva C.G.; Hung A.M.; Liu X.; Murff H.J.; Elasy T.A.; Griffin M.R. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA, 2014, 311, 2288-2296.
48. Ekstrom N.; Svensson A.M.; Miftaraj M.; Franzen S.; Zethelius B.; Eliasson B.; Gudbjornsdottir S. Cardiovascular Safety of Glucose-Lowering Agents as Add-on Medication to Metformin Treatment in Type 2 Diabetes:Report from the Swedish National Diabetes Register (NDR). Diabetes Obes. Metab., 2016, 18, 990-998.
49. Gamble J.M.; Simpson S.H.; Eurich D.T.; Majumdar S.R.; Johnson J.A. Insulin use and increased risk of mortality in type 2 diabetes: A cohort study. Diabetes Obes. Metab., 2010, 12, 47-53.
50. Holden S.E.; Jenkins-Jones S.; Morgan C.L.; Schernthaner G.; Currie C.J. Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: Dose association with allcause mortality, cardiovascular events and cancer. Diabetes Obes. Metab., 2015, 17, 350-362.
51. Bonora E.; Formentini G.; Calcaterra F.; Lombardi S.; Marini F.; Zenari L.; Saggiani F.; Poli M.; Perbellini S.; Raffaelli A.; Cacciatori V.; Santi L.; Targher G.; Bonadonna R.; Muggeo M. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: Prospective data from the Verona Diabetes Complications Study. Diabetes Care, 2002, 25, 1135-1141.
52. Marso S.P.; McGuire D.K.; Zinman B.; Poulter N.R.; Emerson S.S.; Pieber T.R.; Pratley R.E.; Haahr P.M.; Lange M.; Frandsen K.B.; Rabol R.; Buse J.B. Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1. Am. Heart J., 2016, 179, 175-183.
53. Dicker D. DPP-4 inhibitors: Impact on glycemic control and cardiovascular risk factors. Diabetes Care, 2011, 34 Suppl 2, S276-278.
54. Scirica B.M.; Bhatt D.L.; Braunwald E.; Steg P.G.; Davidson J.; Hirshberg B.; Ohman P.; Frederich R.; Wiviott S.D.; Hoffman E.B.; Cavender M.A.; Udell J.A.; Desai N.R.; Mosenzon O.; McGuire D.K.; Ray K.K.; Leiter L.A.; Raz I. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med., 2013, 369, 1317-1326.
55. Scirica B.M.; Braunwald E.; Bhatt D.L. Saxagliptin, alogliptin, and cardiovascular outcomes. N. Engl. J. Med,. 2014, 370, 483-484.
56. White W.B.; Cannon C.P.; Heller S.R.; Nissen S.E.; Bergenstal R.M.; Bakris G.L.; Perez A.T.; Fleck P.R.; Mehta C.R.; Kupfer S.; Wilson C.; Cushman W.C.; Zannad F.; Investigators E. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med., 2013, 369, 1327-1335.
57. Udell J.A.; Cavender M.A.; Bhatt D.L.; Chatterjee S.; Farkouh M.E.; Scirica B.M. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: A meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol., 2015, 3, 356-366.
58. White W.B.; Kupfer S.; Zannad F.; Mehta C.R.; Wilson C.A.; Lei L.; Bakris G.L.; Nissen S.E.; Cushman W.C.; Heller S.R.; Bergenstal R.M.; Fleck P.R.; Cannon C.P.; Investigators E. Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial. Diabetes Care, 2016, 39, 1267-1273.
59. Zannad F.; Cannon C.P.; Cushman W.C.; Bakris G.L.; Menon V.; Perez A.T.; Fleck P.R.; Mehta C.R.; Kupfer S.; Wilson C.; Lam H.; White W.B.; Investigators E. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: A multicentre, randomised, double-blind trial. Lancet, 2015, 385, 2067-2076.
60. Green J.B.; Bethel M.A.; Armstrong P.W.; Buse J.B.; Engel S.S.; Garg J.; Josse R.; Kaufman K.D.; Koglin J.; Korn S.; Lachin J.M.; McGuire D.K.; Pencina M.J.; Standl E.; Stein P.P.; Suryawanshi S.; Van de Werf F.; Peterson E.D.; Holman R.R. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N. Engl. J. Med., 2015, 373, 232-242.
61. McGuire D.K.; Van de Werf F.; Armstrong P.W.; Standl E.; Koglin J.; Green J.B.; Bethel M.A.; Cornel J.H.; Lopes R.D.; Halvorsen S.; Ambrosio G.; Buse J.B.; Josse R.G.; Lachin J.M.; Pencina M.J.; Garg J.; Lokhnygina Y.; Holman R.R.; Peterson E.D.; Trial Evaluating Cardiovascular Outcomes With Sitagliptin Study G. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol., 2016, 1, 126-135.
62. Toh S.; Hampp C.; Reichman M.E.; Graham D.J.; Balakrishnan S.; Pucino F.; Hamilton J.; Lendle S.; Iyer A.; Rucker M.; Pimentel M.; Nathwani N.; Griffin M.R.; Brown N.J.; Fireman B.H. Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study. Ann. Intern. Med., 2016, 164, 705-714.
63. Fu A.Z.; Johnston S.S.; Ghannam A.; Tsai K.; Cappell K.; Fowler R.; Riehle E.; Cole A.L.; Kalsekar I.; Sheehan J. Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study. Diabetes Care, 2016, 39, 726-734.
64. Fadini G.P.; Avogaro A.; Degli Esposti L.; Russo P.; Saragoni S.; Buda S.; Rosano G.; Pecorelli S.; Pani L.; OsMed Health D.B.N. Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: A retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database. Eur. Heart J., 2015, 36, 2454-2462.
65. Johansen O.E.; Neubacher D.; von Eynatten M.; Patel S.; Woerle H.J. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: A pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc. Diabetol., 2012, 11, 3.
66. Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA). ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01897532(Accessed January 8, 2017).
67. Schweizer A.; Dejager S.; Foley J.E.; Couturier A.; Ligueros- Saylan M.; Kothny W. Assessing the cardiocerebrovascular safety of vildagliptin: Meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes. Metab., 2010, 12, 485-494.
68. U.S. Department of Health and Human Services. U.S. Food and Drug Administration. Diabetes Medications Containing Saxagliptin and Alogliptin: Drug Safety Communication – Risk of Heart Failure; April 5 2016. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htm(Accessed July 21, 2016).
69. Kirkman M.S.; Briscoe V.J.; Clark N.; Florez H.; Haas L.B.; Halter J.B.; Huang E.S.; Korytkowski M.T.; Munshi M.N.; Odegard P.S.; Pratley R.E.; Swift C.S. Diabetes in older adults. Diabetes Care, 2012, 35, 2650-2664.
70. Garber A.J. Long-acting glucagon-like peptide 1 receptor agonists: A review of their efficacy and tolerability. Diabetes Care, 2011, 34 Suppl 2, S279-284.
71. Pfeffer M.A.; Claggett B.; Diaz R.; Dickstein K.; Gerstein H.C.; Kober L.V.; Lawson F.C.; Ping L.; Wei X.; Lewis E.F.; Maggioni A.P.; McMurray J.J.; Probstfield J.L.; Riddle M.C.; Solomon S.D.; Tardif J.C. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N. Engl. J. Med., 2015, 373, 2247-2257.
72. Marso S.P.; Daniels G.H.; Brown-Frandsen K.; Kristensen P.; Mann J.F.; Nauck M.A.; Nissen S.E.; Pocock S.; Poulter N.R.; Ravn L.S.; Steinberg W.M.; Stockner M.; Zinman B.; Bergenstal R.M.; Buse J.B.; Investigators L.S.C.o.b.o.t.L.T. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med, 2016, 375, 311-322.
73. Marso S.P.; Bain S.C.; Consoli A.; Eliaschewitz F.G.; Jodar E.; Leiter L.A.; Lingvay I.; Rosenstock J.; Seufert J.; Warren M.L.; Woo V.; Hansen O.; Holst A.G.; Pettersson J.; Vilsboll T.; Investigators S.-. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N. Engl. J. Med., 2016, 375, 1834-1844.
74. Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01144338(Accessed January 8, 2017).
75. A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650. ClinicalTrials. gov. https://clinicaltrials.gov/ct2/show/NCT01455896(Accessed January 8, 2017).
76. Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01394952 (Accessed January 8, 2017).
77. Abdul-Ghani M.; Del Prato S.; Chilton R.; DeFronzo R.A. SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study. Diabetes Care, 2016, 39, 717-725.
78. Zinman B.; Wanner C.; Lachin J.M.; Fitchett D.; Bluhmki E.; Hantel S.; Mattheus M.; Devins T.; Johansen O.E.; Woerle H.J.; Broedl U.C.; Inzucchi S.E. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N. Engl. J. Med., 2015, 373, 2117-2128.
79. Wanner C.; Inzucchi S.E.; Lachin J.M.; Fitchett D.; von Eynatten M.; Mattheus M.; Johansen O.E.; Woerle H.J.; Broedl U.C.; Zinman B.; Investigators E.-R.O. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N. Engl. J. Med., 2016, 375, 323-334.
80. Sattar N.; McLaren J.; Kristensen S.L.; Preiss D.; McMurray J.J. Erratum to: SGLT2 Inhibition and cardiovascular events: Why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia, 2016, 59, 1333-1339.
81. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 2002, 288, 2981-2997.
82. Ingelfinger J.R.; Rosen C.J. Cardiovascular Risk and Sodium-Glucose Cotransporter 2 Inhibition in Type 2 Diabetes. N. Engl. J. Med., 2015, 373, 2178-2179.
83. Ferrannini E.; Mark M.; Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetes Care, 2016, 39, 1108-1114.
84. Mudaliar S.; Alloju S.; Henry R.R. Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis. Diabetes Care, 2016, 39, 1115-1122.
85. CANVAS - CANagliflozin cardioVascular Assessment Study. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01032629(Accessed January 8, 2017).
86. Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02065791 (Accessed January 8, 2017).
87. Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARETIMI58). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01730534 (Accessed January 8, 2017).
88. Canadian Diabetes Association. Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update. Can. J. Diabetes, 2016, 40, 484-486.
89. American Diabetes A. 8. Pharmacologic Approaches to Glycemic Treatment. Diabetes Care, 2017, 40, S64-S74.
90. Athyros V.G.; Katsiki N.; Tentolouris N. Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial. Curr. Vasc. Pharmacol., 2016, 14, 469-473.